Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today ...

This guidance emphasises the potential of NGS methods in mitigating safety risks associated with therapies incorporating ...

The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.

The genome has thousands of genes that code for proteins, which help carry out many of the cell's important functions. But ...

NIH-funded UT team and colleagues from Metagenomi Thereapeutics discovered highly efficient enzyme could enable targeted gene editing within the human body.

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

The US Food and Drug Administration (FDA) today issued a draft guidance for sponsors seeking approval of human gene therapy ...

Most gene-editing tools are blind to context. Point them at a DNA sequence and they cut, whether that sequence sits inside a ...

Scientists at Rothamsted Research have successfully developed wheat with dramatically reduced levels of asparagine, without ...